Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03491683 · ClinicalTrials.gov registry record · Phase 1
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
A Phase 1 study of Glioblastoma, sponsored by Inovio Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT03491683: Active Phase 1 study of Glioblastoma, sponsored by Inovio Pharmaceuticals.
NCT03491683 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by Inovio Pharmaceuticals. The registered enrollment target is 52 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03491683, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by Inovio Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- BIOLOGICAL Cemiplimab
- BIOLOGICAL INO-5401
- BIOLOGICAL INO-9012
Study Locations (20)
New York
- New York University Langone Medical Center; Perlmutter Cancer Center - New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center The Neurological Institute of New York - New York
- New York-Presbyterian Hospital/Weill Cornell Medical Center - New York
California
- City of Hope - Duarte
- Stanford University, School of Medicine - Palo Alto
- University of California, San Francisco - San Francisco
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
- Moffitt Cancer Center - Tampa
Pennsylvania
- University of Pennsylvania Health System: Penn Medicine - Philadelphia
- UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion - Pittsburgh
Texas
- Texas Oncology - Austin
- Baylor College of Medicine - Houston
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-05-31 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT03491683 still lists
NCT03491683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Radiation Therapy is the first listed.
NCT03491683 names 20 study sites across 12 states, led by New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03491683 about?
NCT03491683 is a clinical study titled "INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)". Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
What is the current status of trial NCT03491683?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2018-05-31. Estimated completion is 2026-12-31.
What conditions does trial NCT03491683 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03491683?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Cemiplimab (BIOLOGICAL), INO-5401 (BIOLOGICAL), INO-9012 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03491683?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03491683 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03491683's enrollment target sits among peer trials
52 85th of 199 higher than 114 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI